Cite

HARVARD Citation

    Cui, W. et al. (n.d.). Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. Lung cancer. pp. S38-S39. [Online]. 
  
Back to record